An Open Label Randomized Phase IV Study of the Safety and Efficacy of ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis

Trial Profile

An Open Label Randomized Phase IV Study of the Safety and Efficacy of ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 18 May 2018

At a glance

  • Drugs Corticotropin (Primary)
  • Indications Lupus nephritis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 May 2018 Status changed from recruiting to withdrawn prior to enrolment.
    • 10 Jun 2017 Biomarkers information updated
    • 28 Mar 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2018, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top